Dr. Daniel Royston is an academic Haematopathologist holding a joint University & NHS position. He trained in Medicine & Cellular Pathology before completing his DPhil at the University of Oxford in 2011.
The main focus of his research group is the systematic characterisation of the cellular and stromal interactions within biopsy material that drive the initiation and progression of myeloid blood cancers, with specific focus on myeloproliferative neoplasms (MPN). Their work uses cutting edge techniques in quantitative image analysis, including artificial intelligence (AI) / machine learning approaches. They have successfully demonstrated the utility of these approaches in clinical samples taken from patients, and offered new insights into the fundamental pathological processes driving disease progression and response to therapy. Their work is now employed in the evaluation of several new therapeutics in MPN, and provides clinical trialists with the first robust and objective measures of tissue-based disease modification. Understanding the spatial relationships of key cellular and stromal tissue components and their correlation to genetic and immune / inflammatory factors in myeloid diseases is now the key focus of his research group.
His research involves close multi-disciplinary collaborations between Cellular Pathology, Haematology and Biomedical Engineering (Institute of Biomedical Engineering; Professor Jens Rittscher). Their work is jointly funded by Blood Cancer UK (BCUK) and Cancer Research UK (CRUK).